HC Wainwright Predicts Annexon’s Q1 Earnings (NASDAQ:ANNX)

Annexon, Inc. (NASDAQ:ANNX) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Annexon in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.33) per share for the quarter. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon’s FY2025 earnings at ($1.31) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($0.78) EPS and FY2028 earnings at ($0.28) EPS.

ANNX has been the topic of a number of other research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and set a $16.00 price target on shares of Annexon in a research report on Tuesday. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $15.80.

Annexon Stock Performance

Shares of Annexon stock opened at $2.68 on Friday. Annexon has a 52-week low of $2.30 and a 52-week high of $8.40. The stock has a market cap of $285.67 million, a PE ratio of -2.55 and a beta of 1.14. The firm has a 50-day moving average of $3.80 and a 200-day moving average of $5.36.

Annexon (NASDAQ:ANNX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05).

Institutional Trading of Annexon

Several large investors have recently made changes to their positions in ANNX. JPMorgan Chase & Co. raised its position in Annexon by 16.0% during the third quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company’s stock valued at $10,101,000 after purchasing an additional 235,810 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Annexon by 18.3% during the 3rd quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock worth $12,693,000 after buying an additional 331,269 shares during the last quarter. Barclays PLC lifted its position in shares of Annexon by 212.0% during the 3rd quarter. Barclays PLC now owns 177,765 shares of the company’s stock worth $1,052,000 after buying an additional 120,789 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Annexon by 221.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 732,216 shares of the company’s stock valued at $4,335,000 after buying an additional 504,656 shares in the last quarter. Finally, FMR LLC grew its position in Annexon by 3.2% in the third quarter. FMR LLC now owns 8,561,949 shares of the company’s stock valued at $50,687,000 after acquiring an additional 262,229 shares during the last quarter.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.